

# Amicus® Separator

## Mononuclear Cell (MNC) Collection




**DXT**  
**DATA  
MANAGEMENT  
POWERED**

# Putting precision collections at your fingertips



## Deliver high collection efficiencies

Meeting the patients' clinical needs is always your primary goal. Our design delivers precision collections with the high efficiency required in clinical settings.




# High MNC Collection Efficiency with low platelet loss

## Tailor collections

Every MNC collection is different because every patient and donor is different. Amicus is designed to make it easy to tailor collections for high product purity and high MNC yield.

Longer MNC harvest can be achieved by increasing the RBC Offset to fully capture the MNCs.



	Mobilized Patient <sup>1,†</sup> Median	n	Mobilized Donor <sup>1,†</sup> Median	n	Non-Mobilized Donor <sup>2</sup> Median	n
MNC CE1 (%)	80	87	70	17	NR <sup>†</sup>	12
Platelets (x10 <sup>11</sup> )	0.43	96	0.57	18	0.46 ± 0.15	12
Hematocrit (%)	13.6	62	3.8	14	9.6 ± 2.6	12
Product Volume (mL)	176	97	160	18	50.4 ± 3.5	12

<sup>†</sup>MNC sub-populations were measured for this study. Mean CD34+ CE(%) was 63.7 ±14.9 (±SD).

<sup>‡</sup>Mobilization with G-CSF + chemotherapy for patients and G-CSF alone for healthy subjects per institutional practice.

## Platelet sparing, for your patient and the product

One therapeutic procedure shouldn't result in the need for another. Our design allows you to perform MNC collections on patients with low platelet counts, with reduced risk for post collection platelet transfusions.<sup>3,4</sup>

## Patient and donor comfort

Comfort is a key part of the care you provide. With low extracorporeal volume (ECV) and irradiation-sterilized kits (to avoid the risk of reactions related to residual ethylene oxide), Amicus delivers a safe experience - even for fragile patients or donors.

10%

Median patient platelet loss<sup>1</sup>

191 mL

Optia MNC<sup>6</sup>

163 mL

Amicus<sup>5</sup>

# References

---

1. FCRP-0297: Investigational Plan for the Harvesting of PBSC in G-CSF and Chemotherapy Mobilized Patients Using the Amicus Separator, December, 2000 and Post Hoc Analysis for FCRP-0297, March, 2014. Data on file
  2. Steininger PA, Strasser EF, Weiss D, Achenbach S, Zimmerman R, Ekstein R. First comparative evaluation of a new leukapheresis technology in non-cytokine-stimulated donors. Vox Sanguinis 2013; DOI 10.1111/vox. 12102
  3. Ikeda K, Ohto H, Kanno T, Ogata T, Joji H, Ogawa K, Maruyama Y. Automated programs for collection of mononuclear cells and progenitor cells by two separators for peripheral blood progenitor cell transplantation: comparison by a randomized crossover study. Transfusion. 2007 Jul;47:1234-1240.
  4. Ikeda K, et al. Collection of MNCs and progenitor cells by two separators for PBPC transplantation: a randomized crossover trial. Transfusion. 2003 Jun; 43:814-819.
  5. Fresenius Kabi Operators Manual Amicus MNC
  6. Spectra Optia® Operators Manual MNC
- ‡ Amicus is cleared for MNC collection. Further analysis was performed on collected MNC products using multiparameter flow cytometry; results may vary depending on analysis method.

Together with healthcare professionals, we are committed to making a positive difference with our technologies, training and support.



Refer to the Instructions for Use and Operator's Manual for a complete list of warnings and precautions associated with the use of these products.

Trademarks referred to are property of their respective owners.



US Headquarters:  
Fresenius Kabi  
Three Corporate Drive  
Lake Zurich, IL 60047  
Phone: (847) 550-2300  
[www.fresenius-kabi.us](http://www.fresenius-kabi.us)  
[AmicusTherapeutics@Fresenius-Kabi.com](mailto:AmicusTherapeutics@Fresenius-Kabi.com)

Copyright © 2024 Fresenius Kabi AG. All rights reserved.  
PP-AMTH-US-0002